Clinical Trial Results:
            A Phase IIB, Randomized, Multicenter, Parallel Group Study to Evaluate the Short-Term Safety, Pharmacokinetics and Antiviral Activity of Four Blinded Dosing Regimens of GW640385/Ritonavir Therapy Compared to Open-label Current Protease Inhibitor (PI) therapy in HIV-1 Infected, PI Experienced Adults for 2 weeks with Long-Term Evaluation (> 48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected GW640385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, PI Containing Regimen
    
|     Summary | |
|     EudraCT number | 2005-001150-24 | 
|     Trial protocol | GB DE IT PT | 
|     Global completion date | 
                                    28 Jun 2007
                             | 
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | 
                                        No
                                 | 
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | 
                                        No
                                 | 
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    16 Nov 2016
                             | 
|     First version publication date | 
                                    16 Nov 2016
                             | 
|     Other versions | |
|     Summary report(s) | gsk-hpr20001-synopsis-redact | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
